Molecular interaction studies of amorphous solid dispersions of the antimelanoma agent betulinic acid.

Meiki Yu, Joseph E Ocando, Louis Trombetta, Parnali Chatterjee
Author Information
  1. Meiki Yu: Department of Pharmaceutical Sciences, St. John's University, 8000 Utopia Pkwy, Queens, NY, 11439, USA.

Abstract

Betulinic acid (BA), a novel natural product with antimelanoma activity, has poor aqueous solubility (<0.1 μg/mL) and therefore exhibits poor bioavailability. The purpose of this study was to explore the feasibility of preparing BA solid dispersions (BA-SDs) with hydrophilic polymers to enhance the aqueous solubility of BA. Melt-quenched solid dispersions (MQ-SDs) of BA were prepared at various ratios with the hydrophilic polymers including Soluplus, HPMCAS-HF, Kollidon VA64, Kollidon K90, and Eudragit RLPO. BA was found to be miscible in all polymers at a 1:4 (w/w) ratio by modulated differential scanning calorimetry (MDSC). BA/Soluplus MQ-SD exhibited the highest solubility in simulated body fluids followed by BA/Kollidon VA64 MQ-SD. The MQ-SDs of BA/Soluplus, BA/HPMCAS-HF, and BA/Kollidon VA64 were found to be amorphous as indicated by X-ray powder diffraction (XRPD) studies. Fourier transform infra-red (FT-IR) studies indicated molecular interactions between BA and Soluplus. Our preliminary screening of polymers indicates that Soluplus and Kollidon VA64 exhibit the greatest potential to form BA-SDs.

References

  1. Planta Med. 2007 Feb;73(2):157-62 [PMID: 17415876]
  2. J Pharm Sci. 1971 Sep;60(9):1281-302 [PMID: 4935981]
  3. J Biol Chem. 1998 Dec 18;273(51):33942-8 [PMID: 9852046]
  4. Pharm Res. 1997 Apr;14(4):410-4 [PMID: 9144723]
  5. Bioorg Med Chem Lett. 2001 Sep 3;11(17):2405-8 [PMID: 11527742]
  6. J Drug Target. 2006 Jun;14(5):301-10 [PMID: 16882550]
  7. AAPS PharmSciTech. 2009;10(4):1172-7 [PMID: 19842041]
  8. J Chromatogr A. 2004 Sep 17;1049(1-2):37-42 [PMID: 15499915]
  9. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):799-813 [PMID: 24056053]
  10. J Pharm Sci. 2009 Sep;98(9):2935-53 [PMID: 19499564]
  11. Drug Discov Today. 2009 Sep;14(17-18):885-90 [PMID: 19520182]
  12. Drug Discov Today Technol. 2012 Summer;9(2):e71-e174 [PMID: 24064267]
  13. Int J Pharm. 2010 Aug 16;395(1-2):232-5 [PMID: 20562003]
  14. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):882-8 [PMID: 23567485]
  15. Int J Pharm. 2001 Sep 11;226(1-2):147-61 [PMID: 11532578]
  16. Pharm Res. 2009 Jun;26(6):1419-31 [PMID: 19277850]
  17. J Pharm Sci. 2010 Sep;99(9):4023-31 [PMID: 20607809]
  18. Bioorg Med Chem. 1997 Dec;5(12):2133-43 [PMID: 9459011]
  19. Pharm Res. 1995 Jun;12(6):799-806 [PMID: 7667182]
  20. Int J Pharm. 2012 Jan 17;422(1-2):68-74 [PMID: 22036652]
  21. J Pharm Pharmacol. 2009 Dec;61(12):1571-86 [PMID: 19958579]
  22. Eur J Pharm Biopharm. 2000 Jul;50(1):47-60 [PMID: 10840192]
  23. Cancer Lett. 2007 Jun 18;251(1):132-45 [PMID: 17169485]
  24. Mini Rev Med Chem. 2002 Apr;2(2):163-75 [PMID: 12370077]
  25. Anticancer Drugs. 2010 Mar;21(3):215-27 [PMID: 20075711]
  26. J Biomed Nanotechnol. 2011 Apr;7(2):317-24 [PMID: 21702370]
  27. J Pharm Sci. 2012 Apr;101(4):1355-77 [PMID: 22213468]
  28. J Pharm Sci. 2013 Mar;102(3):967-81 [PMID: 23280631]
  29. Int J Pharm. 2010 May 10;390(2):165-73 [PMID: 20132875]
  30. Cancer Lett. 2002 Jan 10;175(1):17-25 [PMID: 11734332]
  31. Pharm Res. 2009 Nov;26(11):2523-34 [PMID: 19771495]
  32. Drug Dev Ind Pharm. 2004 Jan;30(1):9-17 [PMID: 15000425]
  33. J Pharm Sci. 1997 Jan;86(1):1-12 [PMID: 9002452]
  34. Anticancer Drugs. 2011 Mar;22(3):223-33 [PMID: 21263311]
  35. Curr Med Chem Anticancer Agents. 2002 Jul;2(4):485-537 [PMID: 12678733]
  36. Carbohydr Polym. 2014 Jan 30;101:146-53 [PMID: 24299759]

MeSH Term

Antineoplastic Agents
Biological Availability
Chemistry, Pharmaceutical
Drug Carriers
Hydrophobic and Hydrophilic Interactions
Pentacyclic Triterpenes
Polymers
Powders
Solubility
Triterpenes
Betulinic Acid

Chemicals

Antineoplastic Agents
Drug Carriers
Pentacyclic Triterpenes
Polymers
Powders
Triterpenes
Betulinic Acid

Word Cloud

Created with Highcharts 10.0.0BApolymersVA64solubilitysoliddispersionsSoluplusKollidonstudiesacidantimelanomapooraqueousBA-SDshydrophilicMQ-SDsfoundBA/SoluplusMQ-SDBA/KollidonamorphousindicatedBetulinicnovelnaturalproductactivity<01μg/mLthereforeexhibitsbioavailabilitypurposestudyexplorefeasibilitypreparingenhanceMelt-quenchedpreparedvariousratiosincludingHPMCAS-HFK90EudragitRLPOmiscible1:4w/wratiomodulateddifferentialscanningcalorimetryMDSCexhibitedhighestsimulatedbodyfluidsfollowedBA/HPMCAS-HFX-raypowderdiffractionXRPDFouriertransforminfra-redFT-IRmolecularinteractionspreliminaryscreeningindicatesexhibitgreatestpotentialformMolecularinteractionagentbetulinic

Similar Articles

Cited By